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Statistical Modelsfor Genetic
Susceptibility in Toxicological
and Epidemiological Investigations
by WalterW. Piegorsch
Modelsarepresentedforweinassessinggeneticsusceptibilitytocancer(orotherdiseases) withanimalorhumandata.
Observationsareassumedtobeintheformofproportions, henceabinomialsamplingdistribution isconsidered. Genera-
lizedlinearmodelsareemployedtomodeltheresponseasafunctionofthegeneticcomponent; these includelogisticand
complementary logforms. Susceptibility ismeasuredviaoddsratiosofresponse, relativetoabackgroundgeneticgroup.
g ancestessandconfidenceintervalsfortheseoddsratiosarebasedonmaximumlikelihodestimatesoftheregression
parameters.Additionalconiderationisgiventotheproblemofgene-environment inteactosandtotestingwhethercertain
geneticidentifiers/categoriesmaybecollapsedintoasmallersetofcategories. Thecollapsibilityhypothesis providesan
example ofa mechanistic context wherein nonhierarchical modelsforthe linear predictor can sometimes make sense.
Introduction
Recenttechnologicaladvances inbiomedicalexperimentation
havegreatly improved identificationofgenetic damage (1) and
recognition ofgenetic factors that may affect disease suscep-
tibilitiesinanimal(2)andhuman(3)subjects. Moleculargenetic
techniques are nowusedtoidenitifyspecificgenotypes orgenetic
patterns inindividualsaffectedby somedisease or, forexample,
exhibiting cancer. Forinstance, theroleofgeneticfactors inlung
tumoronsetandprogressionhasbeenrecentlyhighlighted(4-7),
ashavegenetic components inthedevelopmentofhumanblad-
der tumors and other cancers (8-10). To study these effects,
variousbiochemical, cytogenetic, andmolecularprobes areused
(11-14), and epidemiologic research has moved to use these
methods in studiesofdisease/cancer susceptibility (15,16). Ofin-
terest is whether individuals invariousgenetic categoriesdisplay
greater risk of cancer or disease than those identified in some
background, control, orgenetic "wild-type" category. Statistical
modelsandmethods forassessing theserisksinbothanimal ex-
periments and human population studies are described in the
following sections.
Statistical Models: Generalized
Linear Forms
AssumetheexistenceofT>2 genetic susceptibility groups or
categories, identifiedwithout errorvia some formofbiological/
biomolecularprobe, andindexedby i=O,. . ., T-1. Forinstance,
the experimental study design might compare the effects of
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a setofTdifferent genotypes orpolymorphisms on the cancer
or disease under study. The group at i = 0 is considered the
backgroundgrouptowhichsusceptibilitycomparisons aretobe
made. Fromeach prospectively sampled group, acount, Yi, of
individuals exhibiting tumors is recorded. This iscompared to
the total number, Ni, of individuals in each group
(i = 0. . . .T - 1). Forexample, onemightcomparethepropor-
tion of mice developing tumors between two different inbred
strains. The Yis are assumed to take the binomial distribution
(17) with (known) sample size parameter Ni and probability
parameterpi.
As noted above, susceptibility in the ith genetic group is
measured relative to the response in the background, i = 0
group. This is quantifiedvia the odds ratios
1-Pi P0
Tomodel thepiandthe{i, it is naturaltoconsiderthelogistic
form (18)
log ji} = A + Caj (1)
(i=O,...T-1). Thisis ageneralizedlinearmodel (19) thatlinks
a function (here, the logit) of the response probability to the
linearpredictorit + aj. (Inthis over-saturated form, the model
requires an identifiability constraint: ao=O.)
Underthislogisticmodel, theoddsratiostakethesimpleform
Oi=expfxi, Vi. Estimationandtestingofregressionparameters
associated with these odds ratios is performed with computer
programsandpackages such as SAS (20) orGLIM(21) thatfitW. W. PIEGORSCH
the logistic model and provide maximum likelihood (ML)
estimates, likelihhod ratios (LR), etc.
The null effect specifies constant susceptibility relativetothe
backgroundgroup; this corresponds toequality ofodds ratios:
Ho:Wr, = Nf2 = *-- =NfT-1
Under the logistic model, this becomes
Ho: ol=cL2= ...=cTl=
Departures from Ho suggest susceptibility somewhere among
the Tgroups. Oftypical interest is identification ofincreased
cancer susceptibility; this is indicated for the ith group when
0i >1, which occurs under the logistic model ifand only if
ai>0. Thus, tests ofHoagainstone-sided alternatives are readi-
ly available by testing the sign ofai.
To testHoagainst aglobal one-sideddeparture, HI: ca >0,Vi,
(i.e, that all odds ratios exceed one) one appeals to the large-
sample normality ofthe ML estimate &i. A recommended ap-
proach that identifies simultaneously individual departures from
Ho (i.e, which ofthe individual ai are positive) is based on a
modification of the well-known Bonferroni inequality (22).
Begin with the individual Wald test (23)p-values
Pi = 1 -oD &i/se(&i)) ,
wherese(ci,) is the large-sample standard errorof ,i, and c1(.)
is the cumulativedistribution function froma standard normal
distribution. Orderthesevalues fromsmallesttolargest; denote
P(j) as the ith smallest ordered probability. Set the desired
simultaneousconfidencelevelto 1-a. Then, calculatetheindex,
A, which is the largest i such that
va
P(T-1-i+v) > T
(this inequality mustholdforevery valueofv=1, . . .,i, ateach
iunderscrutiny). Concludethatac is significantly greaterthan
0with simultaneousconfidence 1-a, ifPi<a/A. (IfAlcannot
becalcualted, concludethatcaiis significantly greaterthan0at
all levels ofi). Other aspects ofthis and related approaches to
one-sided testing aredescribed indetail elsewhere (24).
Ifa quantification via some intensity variable, say, vi, exists
for each genetic category/group, the logistic model may be
enhancedbyincorporatingthisquantitative information. Asim-
ple (logistic) linearmodel is
og 1PL } -Pi
(i=0,... ,T-1), where it is assumed that v0<vI<... <vT-1.
Under this dose-response model, theodds ratios are
= 0(vj-v0), Vi.
Hence, #j=0 (for all t) ifandonly if0=0, whileOi>l (forall i)
if and only if 0>0. One-sided testing is again of interest,
although ittakes on asimpler formulation inthedose-response
setting, sinceonly one parameter, 0, is assessed. Forexample,
Table 1. Lung tumor susceptibility data.
Group
0.70-kb/0.55-kb
0.70-kb homozygous (i=0) heterozygous (i=l)
lung tumors: 8/16 11/12
the Wald test ofHo:0=0 versus HI:0>0 rejects Ho when 0
Ise(6>z4, whereza, is the 1-a quantile froma standard normal
distribution.
Example 1
Toillustrateuseofthelogistic model inEquation 1, consider
thelungtumorsusceptibilitydatagivenbyRyanetal. (4). These
authors considered susceptibility to the known murine car-
cinogen urethan by examining specific allelic forms ofthe K-
ras-2proto-oncogene inrecombinantoffspringfromcrossesof
inbred strainsofmice. Thesusceptibility allele ischaracterized
byashorterinitialexon(length0.55 kb)comparedtothenormal
allele (length0.70kb). Themiceunderstudy wereknowntobe
eitherhomozygousforthe0.70-kballele, orheterozygous (0.70
kb/0.55 kb). Ifthe0.55-kballeleweretoconferorotherwise in-
dicate increased susceptibility to lung tumorigenesis,
heterozygous mice wouldexhibit greater lung tumor rates and
thusanoddsratiorelativetothehomozygousmicegreaterthan
one.
Thedataforthe T=2 groups are shown in Table 1. Applying
alogistic modeltothesedatagivesanMLestimateoftheregres-
sionparameteras&l = 2.398, with se(&,) = 1.16. AWaldtestof
the nosusceptibilityhypothesisHo:a =0yields ateststatistic of
a
Z= 1 =2.07, se(z)
withone-sidedp-value equalto0.019. FromtheMLestimateof
al, onefindstheMLestimateoftheoddsratiotobeexp[&d] = ,
= 11.0. Large-sample95% confidencelimitsfor^6, aregivenby
exp{ al ± za/2se(a&) I .
Forthesedata, thisyields 1.14 <461<106.45.
Based on this analysis, it seems fair to conclude that the
0.70-kb/0.55-kbheterozygous genotypeexhibitedmoderately in-
creased risk of murine lung tumorigenesis relative to the
homozygousgenotype. Samplesizesaresmall; total samplesof
at least 100 have been suggested to achieve nominal operating
characteristicsinone-sidedtestingunderthelogisticmodel(24).
Thus, furtherexperimentationandanalysisarerequiredbefore
unequivocalconclusions canbe reachedas to theheterozygote
susceptibility inthis setting.
Two-Way Models and Gene-
Environment Interactions
In example 1, only T=2 genetic groups were examined for
murinelungcancersusceptibility. With T=2groups, anumber
ofpossibleanalysescanidentifysusceptibility, including2 x 2
contingency table calculations with x2 tests (25), Fisher exact
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tests (26,27), etc. These approaches often provide similar in-
ferences. Forexample, theone-sidedp-value fromtheFisherex-
act test comparing the two proportions in example 1 is 0.024,
almost identical with thevalue of0.019 achieved with the Wald
test ofaI.
Theusefulnessofthelogisticmodelismoreevident, however,
incaseswithmanygeneticcategoriesoradose-responseunder
study, or when additonal factors orother sourcesofvariability
are identifiedandexaminedaspartofthesusceptibilityanalysis.
For example, with human lung cancer, susceptibility may
associate with genetic effects, lifestyle-related factors such as
cigarette smoking, occupational orenvironmental exposures to
pulmonary genotoxins, or a combination ofthese factors (15).
(Anapplication ofthelogisticmodeltosuchdataispresentedin
example 2, below.) Indeed, recognition isgrowingthatgenetic
susceptibility must be studied in the context of external en-
vironmental exposures thatmightinitiateorcontributetodisease
progression (28). Inthesecases, thelinearpredictorinEquation
1 iseasily extended, andthelogistic modelfacilitatesestimation
ofthe additional parameters.
Considerthecaseoftwofactors: thegenetic factorcontinues
to be indexedby i=0,..., T-1, andanadditional, "environmen-
tal" factor is now considered, indexed by j=O,...,J-1. The
associated two-way extensionofEquation 1 takestheT x Jform
log {1 } = + j + Yij (2)
(i=O,...,T-l; j=0,...,J-1). Asabove, for reasons ofestimability
one assumes that
O=[o0=YO =YOj= Vij.
The interaction parameters in Equation 2, 'yj, relate to the
odds ratios via
zij = in1fvuf/vioviIj},
where
Pij(l-Po)
Iu = POO(l-Pj)
Thus, HO:yij=0 isequivalent to asimplemultiplicative relation-
ship among odds ratios (29-31):
Vij =VioN -
Multiple-level multiplicative interactions are assessed by
simultaneously identifyingequality to0foreach'yijofinterest.
The (T-1)(J-1) degree of freedom (df) hypothesis Ho:-yij=0
( V ij) is equivalent toHo:#ij=OiO&O^, ( v id)k.
Inthoseinstanceswherenodeparturefrommultiplicative in-
teraction is evidenced, itmay beofinterest toestimate various
parameters from the reduced model. For instance, under
6ij =OijO00j, the MLestimateofOij is simply
°j= exp(&a i +
Large-sample 1-a confidence limits for Oijare given by
ecxp{ (i + N ± 7z/2[se2(A&i) +
se2qj) + 2cov(&i,4)IW2),
wherecov(&diA) is theestimated covariance between a andOj.
(Ifeither index is 0thecorresponding standard error will be0
since we setac0=00=0. Similarly, cov(&j3)=0 ifi=0 orj=0.)
Collapsibility
Collapsibility overgeneticcategories isanotherpotentialarea
of interest in studies ofgenetic susceptibility to disease. One
questionswhetherthedifferentgenotypeshaveequivalenteffects
andmaybecollapsed intooneorasmall groupofcategories. For
example, a single-locus, two-allele (say, B and b) system
generates threegeneticcategories: BB,Bb,bb. IfBbehaves as a
simple dominant allele, we cancollapse these three categories
intotwo: B-andbb. Itmaybeofinteresttoassessany suchcol-
lapse statistically.
Obviously, thenatureofthecollapsibility hypothesiswillde-
pend onthegeneunderstudy. Forinstance, ifoneencountered
asituationwherethegeneticfactorisimportanttothedetoxifica-
tionofanenvironmentalexposure, orisimportantineitherpro-
ducing orinactivating atoxicmetabolicproductoftheexposure,
thentheremaybenoapparentgeneticeffectinthoseindividuals
withouttheexposure. Insuchacase, thismay indicatecollapsi-
bility atonlycertainlevelsoftheexposurevariable. Thelogistic
model provides a means for assessing collapsibility ofthis (or
any) sortinthe T x Jsetting. Atanyfixedenvironmental level,
sayj = jo,considercollapsibility overCofthegeneticlevels, in-
dexedbyij,...,ic. This isexpressed as
Under the logistic model, this corresponds to
Ho: ajl + lj0o = i + .= = aic+ylco d
DeparturefromHoisassessedviaageneralizedLRstatistic(32),
for example, with a limiting x2 distribution on C-I df.
Extensions to collapsibility over multiple levels ofj are
straightforward.
Noticethatatj=0 (i.e., atthe "background" environmental
level) the collapsibility hypothesis is
Under the identifiability constraints -yio=0, for all i, this
simplifies to
H ,: ail= %i2= -= a= C
79W. W. PIEGORSCH
Tlble 2. Case-control dataon debrisoquine metabolism forlung cancer.
Metabolization category
PM IM EM
Cases 3 11 116
Controls 9 52 81
Abbreviations: PM, poormetabolizer; IM, intermediatemetabolize, EM, ex-
tensive metabolize.
Thus, collapsibility at the environmental background cor-
responds tocollapsibility amonggenetic maineffects, as would
beexpected. This illustrates asituationwhereanonhierarchial
model (withinteractions,butnotallmaineffects, fullymodeled)
makes sense from a mechanistic perspective, a paradigm not
typically encountered in (generalized) linearmodeling.
Collapsibility canalsobeassessedunderano-interactioncon-
dition, i.e, when yij =0 V ij. The collapsibiltiy hypothesis
becomes
HO: ail0= ai a1iC
atanyj. Thiscondition isindependentofj, however, socollap-
sibility at anyj when 'yij =0Vij corresponds to collapsibility
overallj. Jointcollapsibility follows similarly. Supposecollap-
sibility is considered over the two nonoverlapping categories
indexed byil,...,ic andIl,..,ID. Then,jointcollapsibiltiy is ex-
pressed as a (C-1)+(D-1) dfhypothesis:
Ho Vil=Vi2= *-ic;VIl =VI2= = VID
corresponding to
Ho: il= ai2 = 0Xic ;a,, = a,2 * = CID
Ofcourse, one should have someaprioibasis forconsidering
certain setsofgenetictypesasreasonablecandidatesforcollapse
becauseexploratoryanalysesoverallpossiblecollapsingsrunthe
risk ofdata overinterpretation.
Applications in Epidemiology
Once a potential susceptibility gene has been identified in
humans, its association with disease can be tested in
epidemiologic population studies using case-control study
designs (33). Sampling in a case-control study is carried out
separately forcasesandcontrols inaretrospective mannerand
thus in effect is conditioned on disease status (34). As is well
known, however, onecanreversethisconditioningandmodelthe
logitoftheriskofdiseaseasafunctionofcovariates asinEqua-
tion 1 or2, treatingthedataas iftheyhadarisenprospectively.
Theresultingregressioncoefficientsareasymptoticallyunbiased
for the associated log odds ratios (35,36), and likelihood ratio
testingbasedontheprospectivelogisticmodelisvalidwhenap-
pliedto case-control data(37). Thusthe (prospective) logistic
modelsdescibedaboveareapplicableinretrospective (andpro-
spective) epidemiologic studies wheregenetic susceptibility is
under examination.
Table 3. Interaction of genetic susceptibility evidenced by debrisoquine
phenotype andasbestosexposure.
Cases Controls
Asbestos exposure PM/IM EM PM/IM EM
- 14 97 53 68
+ 3 47 15 17
Abbreviations: PM, poormetabolize; IM, intermediate metabolizer; EM, ex-
tensive metabolizer
Example2
In acase-control study, Caparaso et al. (38) examined indi-
vidual subjects' abilities tometabolizethedrugdebrisoquine and
related thesemetabolic activities to lung cancer susceptibility.
Increased ability to metabolize agents such as debrisoquine is
conjecturedtoindicateincreasedcancersusceptibility because
heterogenity indrug metabolism may associate with heteroge-
neityincancersusceptibility. (Forexample, thedrugmetabolism
pathwaymayplayaroleincarcinogenesis metabolism, eitherby
deactivatingacarcinogenorbyactivatingaproto-carcinogeninto
a carcinogen.) Debrisoquine metabolism is polymorphic in
humans: most individuals receiving the drug rapidly excrete
largeamountsofdebrisoquine metabolite (39); theseindividuals
are "extensive metabolizers" (EM). Some individuals excrete
reducedamountsofthemetaboliteorexcretethedrugalmostun-
changed. Theyare "intermediate" (IM) or "poor" metabolizers
(PM), respectively (5). These polymorphisms lead to T=3
genetic categories for study.
An initial question ofinterest is whetherthe intermediate or
poor metabolizers truly constitute two distinct genetic classes
withrespecttotheirlungcancersusceptibility. Thatis, iscollap-
sibilityevidencedbetweenPMandIM?Tostudythisquestion,
Caporaso et al. (38) reported the case-control data shown in
Table2. Sincethelogisticmodelisapplicabletothisretrospec-
tive sampling scenario (37), weconsidertheprospective form
inEquation I tomodel thegenetic effects. As suggestedabove,
collapsibility ofPMandIMcategoriescorresponds toequality
ofmaineffectsparameters: Ho:ca=a=2. To testthishypothesis,
a GLIM (21) analysis ofthesedatayields a 1 dfLR statistic of
0.178. No significant departure is evidenced, and we conclude
thatthedatasupportthecontentionthatPMandIMmetabolizers
exhibit similarsusceptibilities to lung cancer.
Caporasoetal. (38) alsoreporteddataonthepotential inter-
action ofgenetic susceptibility (as evidenced by debrisoquine
phenotype)andenvironmentalfactors, suchasasbestosexposure
(Table3). Noticethatthedatareflectthepreviousrecognitionof
PM/IMcollapsibility. Referring nowtothetwo-waymodelfrom
Equation2, nointeractionbetweendebrisoquinephenotypeand
asbestos exposure corresponds to testing Ho: mI,=O. The LR
statisticforthissignificancetestis 1.609, on 1 df. Thecorrespon-
dingP-value is 0.205. Noevidence is seen fora significant in-
teraction between the genetic and environmnetal factors.
Data Truncation
Insomesettings, theexperimentalendpointmay involvethe
number of occurrences of some phenomenon, such as the
number oftumors seen in a certain organ ofan experimental
animal(40)orthenumberofcellsinatissueorculturerespon-
ding to a chemical stimulus (41). Denote the random variable
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associated with thisdiscrete-valued responseby U. Iftheobser-
ving mechanism ortechniqueis suchthatonlytheoccurrenceof
a non-null state is recorded (e.g., "no tumors" versus "some
tumors"), thedatawillbetruncatedintoadichotomousresponse.
The observed variable becomes
Y=rl ifU>O
0 difU=O
abinary variatewithprobability ofresponsep=Pr[U>O]. Sobel
and Elashoff (42) have referred to this sampling scheme as
(binomial) "group testing"; also see Chen and Swallow (43).
When interestcentersonthenonresponse, Pr[Y=O], thedataare
often referred to as "Hansen frequencies" (44), based on ap-
plications of E. W. Hansen's work in the behavioral sciences
(45).
This sort of data truncation could occur in a susceptibility
study, wheremultiple tumors occurineach individual, buton-
ly the presence orabsence ofthe cancer is noted. Thus, forthe
kth individual intheithgenetic categoryorgroup, oneobserves
Yik as the indicator ofindividual tumorigenic response. In this
truncation scenario one often takes the Uik as independently
distributed Poisson random variates, with per-group means
following the one-way modeljt+ai (i=O,...,T-1). Thus a new
generalized linear model forpi is induced:
Pi = PrUU >O] = 1 - Pr[U =O] =
1-exp{ - a}).
The result is a complementary log regression equation:
-log{1-Pi) = A + ai * (3)
This construction, based on Poisson occurrence rates, was
discussed indetail by Cochran (46), who had inmind applica-
tion tobacterial concentrations in suspension andtheplanning
ofdilutionexperiments. Hesuggestedthattheconceptwasfairly
wellknown, startingwiththeworkofMcCrady (47) onthecon-
centration oforganisms in liquids.
In general, if a set ofexplanatory variables, X,... ,XE, are
associatedwith Y, ageneralizedlinearmodelcouldbefitunder
thisdatatruncationusingthecomplementarylogregressionwith
linear predictor
° + (01x1 +
... + (I)EXE.
The c parameters are unknown regression coefficients, fit via
maximum likelihood.
Oddsratiosunderthecomplementary logmodelaresomewhat
different from the simpleforms encountered underthelogistic
model inEquation 1. Forthesimpleone-waymodelfromEqua-
tion 3, one has
Vi = exp {al} - e-
1 - e-s
(il T-1). Pointestimatesandlarge-samplestandarderrors
under Equation 3 are still available for ^6, using maximum
likelihood. Also, the null effect model
Ho: V1 = V2 =*-=VT-1 1
again corresponds to
Ho: al = .* = CtT-1= 0
departures fromHocontinueto suggestsusceptibility amongthe
T groups.
Thecomplementary logmodel shareswiththelogisticmodel
thecharacteristic thatincreasedcancersusceptibility, evidenced
when Oti>1, occurs ifand only ifa1>0. Thus, tests ofthe in-
dividual null susceptibility hypothesis Ho:#1=1 against the one-
sidedalternativeHI:Oi>1 are again availableby testing the sign
ofai, insimilarfashion tothelogistic model. Hypothesistesting
extensions to global, one-sided departures are also available
(24).
Example 1 (continued)
Toillustrate useofthecomplementary logmodel fromEqua-
tion3, consideragaintheK-ras-2/lung tumorsusceptibility data
described earlier. For the inbred recombinant mice studied in
that experiment, it is common to observe multiple lung
neoplasms per mouse (4). Reporting the data as dichotomous
outcomesthereforeinvolves a U-pYdatatruncationoftheform
considered herein. The complementary log formulation
becomesaviablemodelcandidate forquantitativeassessmentof
the cancer susceptibility.
Applying acomplementary log model to thesedatagives an
ML estimate of the regression parameter as &1=1.792, with
se(&1) = 0.9895. AWaldtestoftheno-susceptibility hypothesis
Ho:a=0yieldsateststatisticofZ = 1.81, withone-sidedp-value
equal to 0.035. Again, increased susceptibility is evidenced,
although withslightly lessersignificancethanthatexhibitedwith
the logistic analysis. (The call for larger sample sizes remains
valid, and is perhaps in greater evidence here.) Additional
similarity is seen with the ML estimate ofthe odds ratio, con-
structed fromtheMLestimateofa1. Underthecomplementary
log formulation, 0, = 11.003 for these data, an almost in-
distinguishablechangefromthelogisticestimatereportedabove.
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